These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17348107)

  • 1. Are we doing the right phase III trials?
    Burton A
    Lancet Oncol; 2007 Mar; 8(3):193. PubMed ID: 17348107
    [No Abstract]   [Full Text] [Related]  

  • 2. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase III clinical trials in oncology. 20-21 January 2003, London, UK.
    Buyse M
    IDrugs; 2003 Mar; 6(3):187-90. PubMed ID: 12838977
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial watch: phase III and submission failures: 2007-2010.
    Arrowsmith J
    Nat Rev Drug Discov; 2011 Feb; 10(2):87. PubMed ID: 21283095
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase III trials of targeted anticancer therapies: redesigning the concept.
    Ocana A; Amir E; Vera-Badillo F; Seruga B; Tannock IF
    Clin Cancer Res; 2013 Sep; 19(18):4931-40. PubMed ID: 23881926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principle and practice of clinical phase III studies].
    Morant R
    Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 8. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 9. Why did the study fail?
    Dellapasqua S; Castiglione-Gertsch M
    Eur J Cancer; 2005 Dec; 41(18):2784-6. PubMed ID: 16253501
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
    Patsner B
    Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
    [No Abstract]   [Full Text] [Related]  

  • 11. Why do phase III clinical trials in oncology fail so often?
    Amiri-Kordestani L; Fojo T
    J Natl Cancer Inst; 2012 Apr; 104(8):568-9. PubMed ID: 22491346
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 13. Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?
    Dogan M; Erdem GU; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(14):6167-9. PubMed ID: 26320514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting success in phase III studies from phase II results: a new paradigm is needed.
    Leff R; Andrews M
    J Clin Oncol; 2008 Jul; 26(21):3653-4; author reply 3654-5. PubMed ID: 18640948
    [No Abstract]   [Full Text] [Related]  

  • 15. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
    Sivendran S; Newport K; Horst M; Albert A; Galsky MD
    Trials; 2015 Aug; 16():341. PubMed ID: 26253548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
    Markman M
    Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
    Bleehen NM; Ball D; Belani CP; Bishop J; Douillard JY; Cox JD; Johnson DH; Le Chevalier T; Saunders MI; Shaw E
    Lung Cancer; 1994 Mar; 10 Suppl 1():S19-23. PubMed ID: 8087510
    [No Abstract]   [Full Text] [Related]  

  • 18. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
    Giralt S; Stadtmauer E; McCarthy P
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
    [No Abstract]   [Full Text] [Related]  

  • 19. Model aims to reduce discrepancy between phase II, phase III trials.
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1554-5, 1556. PubMed ID: 11018083
    [No Abstract]   [Full Text] [Related]  

  • 20. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.